^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
RPTR-168
i
Other names: RPTR-168, TRQ-1201, Deep IL-12, surface-tethered IL-12, tethered interleukin-12, TRQ1201, Deep IL 12, PRIME IL-12
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Repertoire
Drug class:
IL-12 modulator
Related drugs:
almost2years
RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma (clinicaltrials.gov)
P1/2, N=7, Terminated, Repertoire Immune Medicines | Trial completion date: May 2024 --> Oct 2022 | Active, not recruiting --> Terminated | Trial primary completion date: May 2024 --> Sep 2022; Development program terminated
Trial completion date • Trial termination • Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
PD-1 expression
|
RPTR-168
2years
RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma (clinicaltrials.gov)
P1/2, N=7, Active, not recruiting, Repertoire Immune Medicines | Recruiting --> Active, not recruiting | N=24 --> 7
Enrollment closed • Enrollment change
|
PD-L1 (Programmed death ligand 1) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
PD-1 expression
|
RPTR-168
over3years
RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors (HNSCC, Cervical) and Melanoma (clinicaltrials.gov)
P1/2, N=24, Recruiting, Repertoire Immune Medicines | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
PD-L1 (Programmed death ligand 1)
|
PD-1 expression
|
RPTR-168
over3years
RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors (HNSCC, Cervical) and Melanoma (clinicaltrials.gov)
P1/2, N=24, Not yet recruiting, Repertoire Immune Medicines
Clinical • New P1/2 trial
|
PD-L1 (Programmed death ligand 1)
|
PD-1 expression
|
RPTR-168
Share via
